AP3530A - A novel formulation of naproxen. - Google Patents

A novel formulation of naproxen.

Info

Publication number
AP3530A
AP3530A AP2011005991A AP2011005991A AP3530A AP 3530 A AP3530 A AP 3530A AP 2011005991 A AP2011005991 A AP 2011005991A AP 2011005991 A AP2011005991 A AP 2011005991A AP 3530 A AP3530 A AP 3530A
Authority
AP
ARIPO
Prior art keywords
naproxen
novel formulation
formulation
novel
Prior art date
Application number
AP2011005991A
Other languages
English (en)
Other versions
AP2011005991A0 (en
Inventor
Aaron Dodd
Felix Meiser
Marck Norret
Adrian Russell
H William Bosch
Original Assignee
Iceutica Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2009901746A external-priority patent/AU2009901746A0/en
Application filed by Iceutica Pty Ltd filed Critical Iceutica Pty Ltd
Publication of AP2011005991A0 publication Critical patent/AP2011005991A0/xx
Application granted granted Critical
Publication of AP3530A publication Critical patent/AP3530A/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/02Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of powders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • A61K9/1623Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1635Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00Stock material or miscellaneous articles
    • Y10T428/29Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AP2011005991A 2009-04-24 2010-04-23 A novel formulation of naproxen. AP3530A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17228909P 2009-04-24 2009-04-24
AU2009901746A AU2009901746A0 (en) 2009-04-24 A Novel Formulation of Naproxen
PCT/AU2010/000470 WO2010121326A1 (en) 2009-04-24 2010-04-23 A novel formulation of naproxen

Publications (2)

Publication Number Publication Date
AP2011005991A0 AP2011005991A0 (en) 2011-12-31
AP3530A true AP3530A (en) 2016-01-13

Family

ID=43010609

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2011005991A AP3530A (en) 2009-04-24 2010-04-23 A novel formulation of naproxen.

Country Status (19)

Country Link
US (5) US20120148634A1 (cg-RX-API-DMAC7.html)
EP (1) EP2421512A4 (cg-RX-API-DMAC7.html)
JP (2) JP6116244B2 (cg-RX-API-DMAC7.html)
KR (3) KR20150008909A (cg-RX-API-DMAC7.html)
CN (2) CN103877030A (cg-RX-API-DMAC7.html)
AP (1) AP3530A (cg-RX-API-DMAC7.html)
AU (1) AU2010239085C1 (cg-RX-API-DMAC7.html)
CA (1) CA2759122A1 (cg-RX-API-DMAC7.html)
CO (1) CO6470806A2 (cg-RX-API-DMAC7.html)
EA (1) EA201171284A1 (cg-RX-API-DMAC7.html)
IL (1) IL215868A0 (cg-RX-API-DMAC7.html)
MA (1) MA33299B1 (cg-RX-API-DMAC7.html)
MX (1) MX344222B (cg-RX-API-DMAC7.html)
NZ (2) NZ595985A (cg-RX-API-DMAC7.html)
SG (2) SG10201401720RA (cg-RX-API-DMAC7.html)
TN (1) TN2011000536A1 (cg-RX-API-DMAC7.html)
UA (1) UA111578C2 (cg-RX-API-DMAC7.html)
WO (1) WO2010121326A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201108648B (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008000042A1 (en) 2006-06-30 2008-01-03 Iceutica Pty Ltd Methods for the preparation of biologically active compounds in nanoparticulate form
EP2421510B1 (en) * 2009-04-24 2019-07-31 Iceutica Pty Ltd. Production of encapsulated nanoparticles at commercial scale
NZ620879A (en) 2009-04-24 2015-08-28 Iceutica Pty Ltd A novel formulation of indomethacin
KR101794032B1 (ko) * 2011-09-21 2017-11-07 (주)바이오시네틱스 나노입자 제조방법
WO2015179098A1 (en) 2014-05-21 2015-11-26 Integenx Inc. Fluidic cartridge with valve mechanism
AU2015274801B2 (en) 2014-06-09 2020-10-15 Biometry Inc. Low cost test strip and method to measure analyte
US9526734B2 (en) 2014-06-09 2016-12-27 Iceutica Pty Ltd. Formulation of meloxicam
US11175268B2 (en) 2014-06-09 2021-11-16 Biometry Inc. Mini point of care gas chromatographic test strip and method to measure analytes
GB201506755D0 (en) 2015-04-21 2015-06-03 Reckitt Benckiser Llc Novel pharmaceutical formulation
US10210410B2 (en) 2014-10-22 2019-02-19 Integenx Inc. Systems and methods for biometric data collections
EP3209410B1 (en) 2014-10-22 2024-12-25 IntegenX Inc. Electrophoresis cartridge and corresponding method for sample preparation, processing and analysis
EP3364955B1 (en) 2015-10-09 2022-04-20 RB Health (US) LLC Pharmaceutical formulation
US11364226B2 (en) 2017-06-30 2022-06-21 Cinrx Pharma, Llc Deuterated domperidone compositions, methods, and preparation
KR102851614B1 (ko) 2016-02-04 2025-08-29 신돔 파마, 인크. 장애 치료를 위한 중수소화된 돔페리돈 조성물 및 방법
EP4464772A3 (en) 2016-07-19 2024-12-04 Biometry Inc. Methods of and systems for measuring analytes using batch calibratable test strips
JP7163015B2 (ja) * 2016-10-31 2022-10-31 エスエス製薬株式会社 経口固形組成物
JP2020517578A (ja) * 2017-04-21 2020-06-18 バイオ−シネクティクス インク.Bio−Synectics Inc. 脂質を製粉工程の潤滑剤として用いる活性物質のナノ粒子の製造方法
US12478612B2 (en) 2017-06-30 2025-11-25 Cindome Pharma, Inc. Deuterated domperidone compositions, methods, and preparation
US11779541B2 (en) * 2019-03-26 2023-10-10 Johnson & Johnson Consumer Inc. Immediate release dosage form
CR20230266A (es) * 2020-12-18 2023-07-19 Daewoong Pharmaceutical Co Ltd Nueva formulación para administración oral, que comprende 1-(5-(2,4-difluorofenil)-1-((3-fluorofenil)sulfonil)-4-metoxi-1h-pirrol-3-il)-n-metilmetanamina
KR20250112022A (ko) * 2024-01-16 2025-07-23 피투케이바이오 주식회사 리바록사반 흡입용 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006069419A1 (en) * 2004-12-31 2006-07-06 Iceutica Pty Ltd Nanoparticle composition and methods for synthesis thereof
WO2008000042A1 (en) * 2006-06-30 2008-01-03 Iceutica Pty Ltd Methods for the preparation of biologically active compounds in nanoparticulate form

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2642486B2 (ja) * 1989-08-04 1997-08-20 田辺製薬株式会社 難溶性薬物の超微粒子化法
WO1998035666A1 (en) * 1997-02-13 1998-08-20 Nanosystems Llc Formulations of nanoparticle naproxen tablets
CA2451161A1 (en) * 2001-06-22 2003-01-03 Elan Pharma International, Ltd. Method for high through put screening using a small scale mill or microfluidics
KR20090027734A (ko) * 2006-07-27 2009-03-17 (주)아모레퍼시픽 난용성 약물의 나노입자를 포함하는 분말의 제조방법
CN102438600A (zh) * 2009-04-24 2012-05-02 伊休蒂卡有限公司 用于改善生物活性物质溶出度特征的方法
CN105663045A (zh) * 2009-04-24 2016-06-15 伊休蒂卡有限公司 高体积分数的包封纳米颗粒的制备
EP2421510B1 (en) * 2009-04-24 2019-07-31 Iceutica Pty Ltd. Production of encapsulated nanoparticles at commercial scale
CN104188909A (zh) * 2009-04-24 2014-12-10 伊休蒂卡有限公司 用于制备商品化纳米颗粒和微粒粉末的方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006069419A1 (en) * 2004-12-31 2006-07-06 Iceutica Pty Ltd Nanoparticle composition and methods for synthesis thereof
WO2008000042A1 (en) * 2006-06-30 2008-01-03 Iceutica Pty Ltd Methods for the preparation of biologically active compounds in nanoparticulate form

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BARZEGAR-JALALI ET AL.: 'Evaluation of in vitro- in vivo correlation and anticonvulsive effect of carbamazepine after cogrinding with microcrystalline cellulose' J PHARM PHARMACEUT SCI vol. 9, no. 3, pages 307 - 316, XP008154546 *

Also Published As

Publication number Publication date
ZA201108648B (en) 2013-01-30
AP2011005991A0 (en) 2011-12-31
IL215868A0 (en) 2012-01-31
KR20160135370A (ko) 2016-11-25
JP2012524722A (ja) 2012-10-18
NZ595985A (en) 2014-07-25
SG10201401720RA (en) 2014-06-27
US20150313857A1 (en) 2015-11-05
CN102438592B (zh) 2016-09-14
KR20120104489A (ko) 2012-09-21
AU2010239085A1 (en) 2011-11-10
NZ626401A (en) 2015-12-24
JP6177275B2 (ja) 2017-08-09
US20140200276A1 (en) 2014-07-17
EA201171284A1 (ru) 2012-05-30
SG175767A1 (en) 2011-12-29
WO2010121326A1 (en) 2010-10-28
US20120148634A1 (en) 2012-06-14
CO6470806A2 (es) 2012-06-29
AU2010239085B2 (en) 2014-07-03
UA111578C2 (uk) 2016-05-25
KR20150008909A (ko) 2015-01-23
EP2421512A1 (en) 2012-02-29
MA33299B1 (fr) 2012-05-02
JP2015166379A (ja) 2015-09-24
MX2011011220A (es) 2012-02-08
US20150087709A1 (en) 2015-03-26
EP2421512A4 (en) 2013-01-23
US20160220518A1 (en) 2016-08-04
TN2011000536A1 (en) 2013-05-24
CN103877030A (zh) 2014-06-25
MX344222B (es) 2016-12-07
CN102438592A (zh) 2012-05-02
JP6116244B2 (ja) 2017-04-19
AU2010239085C1 (en) 2014-10-16
CA2759122A1 (en) 2010-10-28

Similar Documents

Publication Publication Date Title
AP3530A (en) A novel formulation of naproxen.
AP2011005989A0 (en) A novel formulation of diclofenac.
AP2011005992A0 (en) A novel formulation of indomethacin.
EP2339918A4 (en) PREPARATION OF A QUINOLINYLOXYDIPHENYLCYCLOPROPANEDICARBOXAMIDE
PT3320979T (pt) Dispensador
ZA201201867B (en) A kettle
AP2011005990A0 (en) A novel formulation of meloxicam.
AU328140S (en) Ring
AU327671S (en) Dispenser
GB2473433B (en) Dispenser
AU327673S (en) Dispenser
AU327672S (en) Dispenser
PL2448460T3 (pl) Dozownik
ZA201006924B (en) Dispenser
GB2475955B (en) Dispenser
GB2470191B (en) Hygroscopic-material dispenser
GB0917897D0 (en) Dispenser
AU2009901746A0 (en) A Novel Formulation of Naproxen
PH32009000427S1 (en) Clinching ring
AU2009904429A0 (en) A Mixer
AU328902S (en) Ring
GB0920850D0 (en) Ring
AU328541S (en) A mixer
GB0911098D0 (en) Handy-Floss Dispenser
GB0920228D0 (en) Dispenser